title: Early [¹⁸F]fluorodeoxyglucose positron emission tomography-based response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: a children's oncology group report.
abstract: The International Harmonization Project defined complete response (CR) after treatment for Hodgkin disease (HD) by absence of fluorodeoxyglucose avidity, regardless of the size of residual masses. Residual avidity after initial treatment is known to predict inferior survival. In the setting of retrieval therapy, early positron emission tomography (PET) scans may improve assessment of treatment efficacy. Retrospective analysis after 2 cycles of gemcitabine and vinorelbine for refractory HD revealed 6 CR among 13 patients by PET and 1 CR in 13 by computed tomography (CT). No relationship between PET response and event-free or overall survival could be discerned, presumably because of the heterogeneity of subsequent therapies.
authors.affiliation: Children's Oncology Group, Arcadia, California, USA. Peter.Cole@Einstein.YU.edu
authors.forename: Peter D
authors.initials: PD
authors.lastname: Cole
authors.forename: Kathleen M
authors.initials: KM
authors.lastname: McCarten
authors.forename: Richard A
authors.initials: RA
authors.lastname: Drachtman
authors.forename: Pedro de
authors.initials: Pd
authors.lastname: Alarcon
authors.forename: Lu
authors.initials: L
authors.lastname: Chen
authors.forename: Tanya M
authors.initials: TM
authors.lastname: Trippett
authors.forename: Cindy L
authors.initials: CL
authors.lastname: Schwartz
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019788:Fluorodeoxyglucose F18; D006689:Hodgkin Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D049268:Positron-Emission Tomography; D012008:Recurrence; D058028:Research Report; D012189:Retrospective Studies; D016019:Survival Analysis; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D019788:Fluorodeoxyglucose F18; D014747:Vinblastine; D000077235:Vinorelbine; D000093542:Gemcitabine